Baseline patient characteristics
| Characteristic . | SNP-A (TET2 seq), n . |
|---|---|
| Median age, y (range) | 68 (19-92) |
| Risk stratification by WHO*† | |
| Low risk | 227 (28) |
| High risk | 169 (31) |
| IPSS risk category† | |
| Low/Int-1 | 199 (27) |
| High/Int-2 | 82 (15) |
| Unclassified | 114 (17) |
| No growth by MC | 19 (5) |
| Clinical data not available | 23 (2) |
| Others‡ | 73 (10) |
| WHO classification | |
| MDS | 235 (14) |
| RA/RCMD/5q− syndrome/MDS-U | 117 (4) |
| RARS/RCMD-RS | 51 (6) |
| RAEB-1/2 | 67 (4) |
| MDS/MPN overlap | 80 (30) |
| CMML-1/2 | 46 (17) |
| MDS/MPN-U§ | 21 (5) |
| RARS-T | 13 (3) |
| JMML | 0 (5) |
| AML | 81 (20) |
| 2° to MDS‖ | 71 (7) |
| 2° to MDS/MPN | 10 (14) |
| 2° to MPN | 1 (1) |
| MPN | 2 (2) |
| Characteristic . | SNP-A (TET2 seq), n . |
|---|---|
| Median age, y (range) | 68 (19-92) |
| Risk stratification by WHO*† | |
| Low risk | 227 (28) |
| High risk | 169 (31) |
| IPSS risk category† | |
| Low/Int-1 | 199 (27) |
| High/Int-2 | 82 (15) |
| Unclassified | 114 (17) |
| No growth by MC | 19 (5) |
| Clinical data not available | 23 (2) |
| Others‡ | 73 (10) |
| WHO classification | |
| MDS | 235 (14) |
| RA/RCMD/5q− syndrome/MDS-U | 117 (4) |
| RARS/RCMD-RS | 51 (6) |
| RAEB-1/2 | 67 (4) |
| MDS/MPN overlap | 80 (30) |
| CMML-1/2 | 46 (17) |
| MDS/MPN-U§ | 21 (5) |
| RARS-T | 13 (3) |
| JMML | 0 (5) |
| AML | 81 (20) |
| 2° to MDS‖ | 71 (7) |
| 2° to MDS/MPN | 10 (14) |
| 2° to MPN | 1 (1) |
| MPN | 2 (2) |
An additional 9 patients screened for TET2 mutation but no SNP-A analysis.
AML indicates acute myelogenous leukemia; FAB, French-American-British; IPSS, International Prognostic Scoring System; JMML, juvenile myelomonocytic leukemia; MC, metaphase cytogenetics; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MDS/MPN-U, MDS/MPN unclassifiable; MDS-U, MDS unclassified; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation; RARS, refractory anemia with ringed sideroblasts; RARS-T, refractory anemia with ringed sideroblasts associated with marked thrombocytosis; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; and WHO, World Health Organization.
Low risk includes RA, RARS, RCMD, RCMD-RS, CMML-1, MDS/MPN-U < 5% blast, RARS-T, MDS-U, and 5q- syndrome. High risk includes RAEB-1/2, CMML-2, MDS/MPN-U ≥ 5% blasts, AML.
Patients with MPN and JMML are excluded.
AML with ≥ 30% BM blast or previously treated prior to sample collection.
One patient is classified as aCML.
Twenty-nine patients are classified as RAEB-T by FAB classification.